FDA cancels Pune Cipla facility's drug sale and distribution licences. Maharashtra Food and Drug Administration has cancelled the drug sale and distribution licences of Cipla Pharma's warehouse in Pune. This decision followed an investigation into alleged violations regarding packaging, storage, and documentation related to Reactin Plus Tablets. The FDA found unauthorized claims on the drug's packaging that constituted misbranding under the Drugs and Cosmetics Act. Cipla expressed disappointment with the decision and stated its commitment.